Biosimilar Monoclonal Antibodies Market By Drug Class (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab) By Application and By Region - Global Forecast To 2026

The global biosimilar monoclonal antibodies market is projected to reach a value of over US$ 32,000.0 Mn in 2026 at a CAGR of 35.7% over the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global biosimilar monoclonal antibodies market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report also offers insightful and detailed information regarding the various key players operating in the global biosimilar monoclonal antibodies market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global biosimilar monoclonal antibodies market report has been segmented on the basis of drug class, application, and region.

Request Covid - 19 Impact

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Global Biosimilar Monoclonal Antibodies Market Dynamics:

Major factor driving growth of the global biosimilar monoclonal antibodies market is patent expiry on essential biological drugs. These patent expiries allow manufacturers to produce biosimilar drugs in bulk quantities and offer it to the general public at much cost-effective rates. Also, a number of pipeline products and increasing cases of chronic and autoimmune diseases are other factors expected to fuel growth of the global biosimilar monoclonal antibodies market over the forecast period. Moreover, recent approvals by prominent regulatory bodies in developed economies for biosimilar monoclonal antibodies is another factor expected to boost adoption of biosimilar MAB and in turn propel growth of the global market to a significant extent.

Report Coverage and Deliverables

PDF report and online dashboard will help you understand:

• Competitive benchmarking
• Market forecasts
• Company market shares
• Market opportunities
• Latest trends & dynamics

Request a Free Sample Copy

View Infographic

However, unfavorable regulatory scenarios in multiple regions coupled with lack of proper reimbursement policies for biosimilar products are major factors restraining growth of the global biosimilar monoclonal antibodies market. Additionally, possible side effects of monoclonal antibodies (MAB) products is another factor anticipated to hamper growth of the global monoclonal antibodies market over the forecast period.

A major and rising trend witnessed in the global biosimilar monoclonal antibodies market is increasing number of biosimilar monoclonal antibody products being developed and offered for use to the general public. This is another factor anticipated to propel growth of the global market over the forecast period.

Global Biosimilar Monoclonal Antibodies Market Segment Analysis:

Analysis by Drug Class:

On the basis of drug class segmentation, Adalimumab segment is estimated to account for major revenue share in the global market and is projected to register highest CAGR of around 37.0% over the forecast period. This can be attributed to increasing incidence of chronic psoriasis and Crohn's disease for which Adalimumab is used as a primary medication. It is commercially available under the trade name Humira.  Also, the Adalimumab segment in the global biosimilar monoclonal antibodies market is projected to maintain its dominant revenue contribution in the global market over the forecast period.

Also, the Abciximab segment is anticipated to register lowest CAGR of around 33.0%, as compared to the other drug class segments in the global biosimilar monoclonal antibodies market. This can be attributed to patent expiry on Abciximab in major revenue contributing countries such as US and Germany.

Moreover, the Infliximab segment among the drug class segments is estimated to account for second-highest revenue share in the global biosimilar monoclonal antibodies market, owing to increasing use of infliximab for treatment of diseases such as rheumatoid arthritis and ulcerative colitis.

Analysis by Application:

Among the application segments, the oncology segment accounted for highest revenue share in the global biosimilar monoclonal antibodies market, and is expected to register highest CAGR of around 38.0% during the forecast period 2017 & 2026. It is further projected to maintain its dominant revenue contribution over the forecast period, owing to increasing use of biosimilar monoclonal antibodies (MAB) in the field of oncology in developed and developing economies.

The chronic and autoimmune diseases segment is projected to account for second-highest revenue share contribution in the global market, and register a CAGR of around 35.0% over the forecast period. This can be attributed to increasing incidence of chronic and autoimmune diseases and high adoption of biosimilar MAB for treatment of these diseases.

Revenue from the others segment is anticipated to grow moderately over the forecast period, and is projected to register a CAGR of around 30.0% over the forecast period.

Analysis by Region:

The market in the Americas dominated the global biosimilar monoclonal antibodies market in revenue terms, and is estimated to account for largest market revenue contribution of US$ 618.4 million in 2017 as compared to that of markets in other regions. It is further expected to maintain its dominant revenue contribution in the global biosimilar monoclonal antibodies market over the forecast period. This can be attributed to presence of advanced healthcare facilities, growing demand for biosimilar products, and increasing adoption of biosimilar monoclonal antibodies in the region.

Moreover, high rate of approvals for biosimilar monoclonal antibodies (MAB) by the Food and Drug Administration (FDA) in recent times is also a major factor boosting growth of the Americas market. Also, high number of pipeline drugs in the Americas market is a major factor for growth of the Americas biosimilar monoclonal antibodies market.

For instance, the United States Food and Drug Administration (FDA) approved Celltrion’s “Inflectra” a biosimilar to Remicade (infliximab) on 5th April 2016, which is the second biosimilar monoclonal antibody to be approved for sale in the US. The market in the US is anticipated to benefit the most from this approval as penetration of biosimilar monoclonal antibodies is highest in the country and there is significant presence of major healthcare facilities in the country.

The Europe market for biosimilar monoclonal antibodies is expected to account for second-highest revenue share in the global market, with an estimated value of around US$ 750.0 million in 2017. This is attributed to increasing adoption of biosimilar monoclonal antibodies and high rate of approval for biosimilar monoclonal antibodies (MAB) in countries in the region.

The market in Asia Pacific is projected to register highest CAGR of around 36.0% over the forecast period, and is expected to be valued around US$ 8,900.0 Mn in 2026. Increasing number of government initiatives for development of healthcare facilities in emerging economies such as China, Japan, and India and increasing adoption of biosimilar products are key factors expected to propel growth of the Asia Pacific market over the forecast period.

Moreover, markets in Latin America and Middle East & Africa are also projected to witness moderate growth over the forecast period due to increasing number of advanced healthcare facilities in the region.

Global Biosimilar Monoclonal Antibodies Market Segmentation:

Global biosimilar monoclonal antibodies segmentation, by drug class:

• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab

Global biosimilar monoclonal antibodies segmentation, by application:

• Oncology
• Chronic and Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Others

Global biosimilar monoclonal antibodies segmentation, by region:

• The Americas
• Europe
• Asia Pacific
• Rest of World